Eurobio Scientific (France) Today

ALERS Stock   25.75  0.05  0.19%   

Performance

15 of 100

 
Weak
 
Strong
Good

Odds Of Distress

Less than 9

 
High
 
Low
Low
Eurobio Scientific is selling at 25.75 as of the 21st of November 2024; that is 0.19% down since the beginning of the trading day. The stock's last reported lowest price was 25.7. Eurobio Scientific has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. Equity ratings for Eurobio Scientific SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.

Moving together with Eurobio Stock

  0.89ALSGD SpineguardPairCorr

Moving against Eurobio Stock

  0.83EAPI Euroapi SASPairCorr
  0.81AFME Affluent Medical SASPairCorr
  0.76ALDMS Diagnostic MedicalPairCorr
  0.68DG Vinci SAPairCorr
  0.45TTE TotalEnergies SEPairCorr
  0.41MC LVMH Mot HennessyPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Eurobio Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Eurobio Scientific's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Eurobio Scientific or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Business ConcentrationMedical Devices, Healthcare (View all Sectors)
Eurobio Scientific SA (ALERS) is traded on Euronext Paris in France and employs 148 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 205.71 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eurobio Scientific's market, we take the total number of its shares issued and multiply it by Eurobio Scientific's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Eurobio Scientific operates under Healthcare sector and is part of Medical Devices industry. The entity has 11.34 M outstanding shares. Eurobio Scientific SA has accumulated about 102.39 M in cash with 65.92 M of positive cash flow from operations.
Check Eurobio Scientific Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Eurobio Scientific is USD205.71 Million. Eurobio Scientific SA retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Check Eurobio Ownership Details

Eurobio Scientific Risk Profiles

Although Eurobio Scientific's alpha and beta are two of the key measurements used to evaluate Eurobio Scientific's performance over the market, the standard measures of volatility play an important role as well.

Eurobio Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Eurobio Scientific without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Volatility Now

   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module

Eurobio Scientific Corporate Management

Elected by the shareholders, the Eurobio Scientific's board of directors comprises two types of representatives: Eurobio Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eurobio. The board's role is to monitor Eurobio Scientific's management team and ensure that shareholders' interests are well served. Eurobio Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eurobio Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.

Additional Tools for Eurobio Stock Analysis

When running Eurobio Scientific's price analysis, check to measure Eurobio Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eurobio Scientific is operating at the current time. Most of Eurobio Scientific's value examination focuses on studying past and present price action to predict the probability of Eurobio Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eurobio Scientific's price. Additionally, you may evaluate how the addition of Eurobio Scientific to your portfolios can decrease your overall portfolio volatility.